ŌURA has signalled an entry into the consumer diabetes space, offering a new glucose feature for its ring that uses insights from Dexcom’s over-the-counter (OTC) continuous glucose monitor (CGM) Stelo ...
Four years ago, my life changed after a heart attack at the age of 33. While a quick coronary angioplasty meant my heart was mostly fine, the tests conducted at the same time revealed a bigger chronic ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...
San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
San Diego device maker Dexcom has received the first FDA clearance for a continuous glucose monitor that doesn’t require a doctor’s prescription. The U.S. Food and Drug Administration cleared Dexcom’s ...
(Reuters) -Dexcom said on Monday its over-the-counter continuous glucose monitor, Stelo, is now available for use in the United States at a price of up to $99. Stelo was cleared by the U.S. health ...
DexCom Inc. DXCM recently announced the launch of a proprietary Generative AI (GenAI) platform, making Dexcom the first Continuous Glucose Monitoring (CGM) manufacturer to integrate GenAI into glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback